Segurança do uso da cabergolina na embriogênese e na gestação

Abstract

Cabergoline is a dopaminergic agonist and exhibits a suppression effect on prolactin. It is used to treat hyperprolactinemia in infertile patients and to prevent the ovarian hyperstimulation syndrome in vitro fertilization cycles. ObjetiveA systematic review on the literature looking for studies that evaluate the safety use of Cabergoline in the embryogenesis and in pregnancy. MethodSystematic review of articles published in last 23 years that try to establish the relationship between the use of Cabergoline in the gestational period with a possible teratogenic effect. The papers were available in the following scientific databases: Medline, Lilacs e Scielo. The key words used were cabergoline, pregnancy and teratogen. ResultsTwelve articles published from 1994 to 2013 were selected. It has been found that 800 pregnant women were exposed to cabergoline. Most of the papers analysed showed that the cabergoline is a safety alternative for theconceptus and for the pregnancy outcome. Its use did not increase the risk of fetal malformation, miscarriage and premature birth. ConclusionData regarding the use of cabergoline during pregnancy have become increasingly consistent, and most articles have demonstrated the reliability and safety of this drug.